Business Description
Remus Pharmaceuticals Ltd
ISIN : INE0O5T01011
Total Employee Number:
68Compare
Compare
Traded in other countries / regions
REMUS.India IPO Date
2023-05-29Description
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.03 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 0.43 | |||||
Interest Coverage | 36.68 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.96 | |||||
Beneish M-Score | -1.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | 184.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.11 | |||||
9-Day RSI | 47.46 | |||||
14-Day RSI | 49.85 | |||||
3-1 Month Momentum % | 9.26 | |||||
6-1 Month Momentum % | -3.82 | |||||
12-1 Month Momentum % | -23.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.98 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 37.56 | |||||
Days Sales Outstanding | 56.37 | |||||
Days Payable | 44.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.13 | |||||
Dividend Payout Ratio | 0.03 | |||||
Forward Dividend Yield % | 0.13 | |||||
5-Year Yield-on-Cost % | 0.13 | |||||
3-Year Average Share Buyback Ratio | 7.1 | |||||
Shareholder Yield % | 0.17 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 13.05 | |||||
Operating Margin % | 6.32 | |||||
Net Margin % | 4.33 | |||||
EBITDA Margin % | 7.43 | |||||
FCF Margin % | 0.42 | |||||
OCF Margin % | 2.13 | |||||
ROE % | 12.14 | |||||
ROA % | 7.03 | |||||
ROIC % | 10.72 | |||||
ROC (Joel Greenblatt) % | 65.38 | |||||
ROCE % | 16.33 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 19.36 | |||||
PE Ratio without NRI | 19.36 | |||||
Price-to-Owner-Earnings | 393.94 | |||||
PS Ratio | 0.84 | |||||
PB Ratio | 2.03 | |||||
Price-to-Tangible-Book | 2.09 | |||||
Price-to-Free-Cash-Flow | 203.65 | |||||
Price-to-Operating-Cash-Flow | 39.67 | |||||
EV-to-EBIT | 14.89 | |||||
EV-to-EBITDA | 14.25 | |||||
EV-to-Revenue | 1.06 | |||||
EV-to-FCF | 254.37 | |||||
Price-to-GF-Value | 0.37 | |||||
Price-to-Graham-Number | 1.34 | |||||
| Price-to-Net-Current-Asset-Value | 10.69 | |||||
Earnings Yield (Greenblatt) % | 6.72 | |||||
FCF Yield % | 0.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Remus Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 8,536.3 | ||
| EPS (TTM) (₹) | 39.19 | ||
| Beta | 1.1579 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 0.85 | ||
| Volatility % | 28.75 | ||
| 14-Day RSI | 49.85 | ||
| 14-Day ATR (₹) | 33.657559 | ||
| 20-Day SMA (₹) | 764.99 | ||
| 12-1 Month Momentum % | -23.41 | ||
| 52-Week Range (₹) | 580 - 993.95 | ||
| Shares Outstanding (Mil) | 11.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Remus Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Remus Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 0.500000 Cash Dividend | 2025-11-14 | 764.25 (-2.39%) | ||
| INR 0.500000 Cash Dividend | 2025-09-18 | 811.25 (-1.48%) | ||
| 2:1 Stock Split | 2025-07-04 | 968.63 (+1.75%) | ||
| INR 0.500000 Cash Dividend | 2024-11-19 | 1,147.00 (-2.80%) | ||
| 4:1 Stock Split | 2024-06-06 | 903.49 (+1.82%) |
Show
Entries
Remus Pharmaceuticals Ltd Frequently Asked Questions
What is Remus Pharmaceuticals Ltd(NSE:REMUS)'s stock price today?
The current price of NSE:REMUS is ₹758.80. The 52 week high of NSE:REMUS is ₹993.95 and 52 week low is ₹580.00.
When is next earnings date of Remus Pharmaceuticals Ltd(NSE:REMUS)?
The next earnings date of Remus Pharmaceuticals Ltd(NSE:REMUS) is .
Does Remus Pharmaceuticals Ltd(NSE:REMUS) pay dividends? If so, how much?
The Dividend Yield %  of Remus Pharmaceuticals Ltd(NSE:REMUS) is 0.13% (As of Today), Highest Dividend Payout Ratio of Remus Pharmaceuticals Ltd(NSE:REMUS) was 0.03. The lowest was 0.02. And the median was 0.03. The  Forward Dividend Yield % of Remus Pharmaceuticals Ltd(NSE:REMUS) is 0.13%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Remus Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers